Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Carriers | 38 | 2024 | 706 | 7.110 |
Why?
|
| Nanoparticles | 38 | 2024 | 1958 | 6.500 |
Why?
|
| Nanocapsules | 10 | 2021 | 94 | 5.460 |
Why?
|
| Lactoferrin | 17 | 2023 | 100 | 5.250 |
Why?
|
| Drug Delivery Systems | 34 | 2024 | 2226 | 4.930 |
Why?
|
| Caseins | 11 | 2018 | 104 | 4.400 |
Why?
|
| Flutamide | 10 | 2018 | 95 | 3.860 |
Why?
|
| Antineoplastic Agents | 30 | 2024 | 13642 | 3.030 |
Why?
|
| Zein | 8 | 2019 | 8 | 2.800 |
Why?
|
| Berberine | 5 | 2018 | 26 | 2.600 |
Why?
|
| Micelles | 10 | 2020 | 192 | 2.380 |
Why?
|
| Polymers | 11 | 2021 | 1616 | 1.890 |
Why?
|
| Nanomedicine | 10 | 2024 | 289 | 1.770 |
Why?
|
| Androstadienes | 4 | 2019 | 348 | 1.760 |
Why?
|
| Gene Transfer Techniques | 5 | 2017 | 1206 | 1.710 |
Why?
|
| Nanocomposites | 5 | 2020 | 49 | 1.670 |
Why?
|
| Nanostructures | 4 | 2018 | 552 | 1.520 |
Why?
|
| Delayed-Action Preparations | 9 | 2018 | 962 | 1.500 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2019 | 621 | 1.440 |
Why?
|
| Particle Size | 18 | 2022 | 1648 | 1.420 |
Why?
|
| Genistein | 3 | 2020 | 86 | 1.350 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 12 | 2020 | 398 | 1.350 |
Why?
|
| Ellagic Acid | 2 | 2020 | 5 | 1.340 |
Why?
|
| Quantum Dots | 3 | 2019 | 167 | 1.290 |
Why?
|
| Phytotherapy | 6 | 2022 | 296 | 1.260 |
Why?
|
| Lipids | 6 | 2020 | 3341 | 1.230 |
Why?
|
| Neoplasms | 15 | 2024 | 22173 | 1.160 |
Why?
|
| Lung Neoplasms | 12 | 2024 | 13381 | 1.150 |
Why?
|
| Chemistry, Pharmaceutical | 7 | 2019 | 274 | 1.140 |
Why?
|
| Protamines | 2 | 2017 | 112 | 1.120 |
Why?
|
| Albumins | 4 | 2019 | 575 | 1.070 |
Why?
|
| Aromatase Inhibitors | 3 | 2019 | 513 | 1.050 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2019 | 2297 | 1.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2014 | 1520 | 0.990 |
Why?
|
| Drug Compounding | 6 | 2020 | 246 | 0.980 |
Why?
|
| Breast Neoplasms | 12 | 2022 | 21019 | 0.940 |
Why?
|
| Phospholipids | 5 | 2020 | 786 | 0.930 |
Why?
|
| Liver Neoplasms | 5 | 2024 | 4317 | 0.910 |
Why?
|
| Proteins | 6 | 2020 | 6032 | 0.870 |
Why?
|
| Surface Properties | 9 | 2020 | 1161 | 0.790 |
Why?
|
| Polysaccharides | 2 | 2018 | 1014 | 0.780 |
Why?
|
| Flavins | 2 | 2018 | 18 | 0.770 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2018 | 321 | 0.760 |
Why?
|
| Sirolimus | 3 | 2018 | 1533 | 0.760 |
Why?
|
| Solubility | 9 | 2020 | 1091 | 0.760 |
Why?
|
| Disaccharides | 2 | 2019 | 170 | 0.750 |
Why?
|
| Tretinoin | 3 | 2020 | 519 | 0.700 |
Why?
|
| Etoposide | 2 | 2018 | 634 | 0.690 |
Why?
|
| Animals | 54 | 2024 | 168475 | 0.690 |
Why?
|
| Stilbenes | 2 | 2017 | 155 | 0.670 |
Why?
|
| Hesperidin | 1 | 2019 | 18 | 0.670 |
Why?
|
| Chondroitin | 2 | 2020 | 64 | 0.670 |
Why?
|
| Iridoids | 3 | 2015 | 18 | 0.660 |
Why?
|
| Exosomes | 1 | 2024 | 424 | 0.650 |
Why?
|
| Diosmin | 1 | 2018 | 6 | 0.640 |
Why?
|
| Silicon Dioxide | 1 | 2020 | 216 | 0.630 |
Why?
|
| Magnetite Nanoparticles | 1 | 2020 | 318 | 0.620 |
Why?
|
| Freeze Drying | 4 | 2011 | 101 | 0.620 |
Why?
|
| Monascus | 1 | 2018 | 1 | 0.620 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2018 | 287 | 0.610 |
Why?
|
| Sulfasalazine | 1 | 2018 | 84 | 0.610 |
Why?
|
| Technology, Pharmaceutical | 1 | 2018 | 84 | 0.610 |
Why?
|
| Nitriles | 3 | 2019 | 971 | 0.610 |
Why?
|
| Hyaluronic Acid | 2 | 2018 | 483 | 0.590 |
Why?
|
| Glutathione | 1 | 2020 | 583 | 0.590 |
Why?
|
| Hep G2 Cells | 4 | 2019 | 379 | 0.590 |
Why?
|
| NF-kappa B | 3 | 2020 | 2490 | 0.570 |
Why?
|
| Polyethylene Glycols | 3 | 2018 | 1189 | 0.570 |
Why?
|
| Cross-Linking Reagents | 7 | 2018 | 687 | 0.570 |
Why?
|
| Nanotechnology | 2 | 2019 | 714 | 0.530 |
Why?
|
| Mice, Inbred BALB C | 8 | 2019 | 6214 | 0.520 |
Why?
|
| Administration, Inhalation | 5 | 2020 | 1157 | 0.520 |
Why?
|
| Gelatin | 2 | 2015 | 220 | 0.500 |
Why?
|
| Doxorubicin | 2 | 2018 | 2224 | 0.480 |
Why?
|
| Tablets | 1 | 2015 | 148 | 0.480 |
Why?
|
| Plant Extracts | 1 | 2018 | 497 | 0.480 |
Why?
|
| Folic Acid | 2 | 2018 | 1323 | 0.470 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 306 | 0.460 |
Why?
|
| Mice | 23 | 2024 | 81539 | 0.460 |
Why?
|
| Boronic Acids | 1 | 2018 | 915 | 0.460 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2020 | 8181 | 0.430 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2012 | 24 | 0.420 |
Why?
|
| Drug Stability | 5 | 2020 | 291 | 0.410 |
Why?
|
| Triazoles | 1 | 2017 | 903 | 0.390 |
Why?
|
| Tissue Distribution | 7 | 2021 | 2264 | 0.380 |
Why?
|
| Carcinoma, Ehrlich Tumor | 3 | 2020 | 23 | 0.380 |
Why?
|
| Drug Synergism | 3 | 2020 | 1757 | 0.370 |
Why?
|
| Nanoconjugates | 3 | 2023 | 21 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2811 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 3605 | 0.360 |
Why?
|
| Rats | 10 | 2023 | 23741 | 0.350 |
Why?
|
| Humans | 58 | 2024 | 761596 | 0.340 |
Why?
|
| Cell Survival | 5 | 2020 | 5791 | 0.330 |
Why?
|
| Oleic Acid | 2 | 2020 | 92 | 0.330 |
Why?
|
| Egypt | 2 | 2019 | 97 | 0.320 |
Why?
|
| Nanospheres | 2 | 2018 | 21 | 0.320 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2020 | 1541 | 0.320 |
Why?
|
| Calorimetry, Differential Scanning | 3 | 2013 | 100 | 0.290 |
Why?
|
| Luteolin | 2 | 2018 | 13 | 0.290 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2019 | 140 | 0.290 |
Why?
|
| Tissue Engineering | 1 | 2018 | 1868 | 0.290 |
Why?
|
| Immunotherapy | 4 | 2024 | 4652 | 0.290 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 16990 | 0.280 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 718 | 0.270 |
Why?
|
| Biological Products | 1 | 2016 | 914 | 0.270 |
Why?
|
| Quinazolines | 1 | 2012 | 1371 | 0.260 |
Why?
|
| Static Electricity | 2 | 2018 | 261 | 0.260 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 3878 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 11742 | 0.260 |
Why?
|
| Androgens | 1 | 2013 | 1286 | 0.250 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 1089 | 0.250 |
Why?
|
| Amino Acids | 1 | 2011 | 1718 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 5368 | 0.240 |
Why?
|
| Neutrophil Activation | 3 | 2020 | 180 | 0.230 |
Why?
|
| Polyphosphates | 2 | 2013 | 17 | 0.220 |
Why?
|
| Drug Combinations | 3 | 2020 | 2048 | 0.220 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 6938 | 0.210 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2022 | 38 | 0.200 |
Why?
|
| Plant Proteins | 2 | 2017 | 370 | 0.200 |
Why?
|
| Neutrophils | 3 | 2020 | 3767 | 0.200 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2013 | 161 | 0.200 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 11122 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2024 | 10451 | 0.200 |
Why?
|
| Administration, Oral | 3 | 2018 | 4021 | 0.190 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2021 | 2496 | 0.190 |
Why?
|
| Glutaral | 2 | 2018 | 76 | 0.190 |
Why?
|
| Pharmaceutical Solutions | 2 | 2011 | 15 | 0.180 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2020 | 35 | 0.180 |
Why?
|
| Biological Availability | 2 | 2011 | 390 | 0.170 |
Why?
|
| Boron | 1 | 2019 | 37 | 0.170 |
Why?
|
| Glycyrrhetinic Acid | 1 | 2019 | 15 | 0.170 |
Why?
|
| Diethylnitrosamine | 1 | 2019 | 45 | 0.170 |
Why?
|
| Hydrogels | 2 | 2018 | 720 | 0.160 |
Why?
|
| Liquid Crystals | 1 | 2019 | 22 | 0.160 |
Why?
|
| Porosity | 1 | 2020 | 349 | 0.160 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2019 | 34 | 0.160 |
Why?
|
| Inorganic Chemicals | 1 | 2018 | 10 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 6312 | 0.150 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2018 | 174 | 0.150 |
Why?
|
| Amitriptyline | 1 | 2017 | 112 | 0.140 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 629 | 0.140 |
Why?
|
| Calibration | 2 | 2020 | 818 | 0.140 |
Why?
|
| Antidotes | 1 | 2017 | 138 | 0.140 |
Why?
|
| Flavonoids | 1 | 2020 | 445 | 0.140 |
Why?
|
| Intestinal Absorption | 1 | 2017 | 400 | 0.130 |
Why?
|
| Biocompatible Materials | 2 | 2018 | 1685 | 0.130 |
Why?
|
| Lectins | 1 | 2018 | 491 | 0.130 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2021 | 774 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2018 | 597 | 0.130 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 713 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 1993 | 0.130 |
Why?
|
| Molecular Structure | 1 | 2020 | 1880 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2018 | 642 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 6131 | 0.120 |
Why?
|
| Gliadin | 1 | 2015 | 80 | 0.120 |
Why?
|
| Laboratories | 1 | 2018 | 458 | 0.120 |
Why?
|
| Muramidase | 1 | 2015 | 169 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2020 | 1892 | 0.120 |
Why?
|
| Milk Proteins | 1 | 2015 | 163 | 0.120 |
Why?
|
| Acute Lung Injury | 1 | 2018 | 367 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 3076 | 0.120 |
Why?
|
| Rats, Wistar | 1 | 2017 | 1848 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2023 | 1590 | 0.110 |
Why?
|
| Elastin | 1 | 2015 | 298 | 0.110 |
Why?
|
| Ligands | 1 | 2020 | 3272 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2024 | 4142 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 1809 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 1229 | 0.100 |
Why?
|
| Ultraviolet Rays | 2 | 2020 | 1080 | 0.100 |
Why?
|
| Desiccation | 1 | 2012 | 78 | 0.100 |
Why?
|
| Male | 14 | 2020 | 360846 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 754 | 0.100 |
Why?
|
| Rabbits | 1 | 2018 | 4772 | 0.100 |
Why?
|
| Female | 10 | 2019 | 392705 | 0.090 |
Why?
|
| Povidone | 1 | 2011 | 30 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 2539 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2013 | 731 | 0.090 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 934 | 0.090 |
Why?
|
| Excipients | 1 | 2011 | 98 | 0.090 |
Why?
|
| Poloxamer | 1 | 2011 | 56 | 0.090 |
Why?
|
| Psoriasis | 1 | 2019 | 950 | 0.090 |
Why?
|
| Plants | 1 | 2012 | 327 | 0.090 |
Why?
|
| Lung | 5 | 2020 | 10002 | 0.090 |
Why?
|
| X-Ray Diffraction | 1 | 2011 | 421 | 0.090 |
Why?
|
| Solutions | 1 | 2011 | 412 | 0.090 |
Why?
|
| Apoptosis | 2 | 2018 | 9490 | 0.090 |
Why?
|
| Tensile Strength | 1 | 2011 | 330 | 0.090 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2015 | 740 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 4176 | 0.080 |
Why?
|
| beta-Cyclodextrins | 1 | 2009 | 70 | 0.080 |
Why?
|
| Chitosan | 1 | 2011 | 131 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 957 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2330 | 0.080 |
Why?
|
| Brain | 1 | 2016 | 27121 | 0.080 |
Why?
|
| Analgesics | 1 | 2016 | 1070 | 0.080 |
Why?
|
| Crystallization | 1 | 2009 | 534 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 1935 | 0.070 |
Why?
|
| Microspheres | 1 | 2011 | 784 | 0.070 |
Why?
|
| Wound Healing | 1 | 2019 | 2805 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10766 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3492 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8527 | 0.070 |
Why?
|
| Phenotype | 1 | 2024 | 16592 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2021 | 64685 | 0.060 |
Why?
|
| Skin | 1 | 2018 | 4484 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8554 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2018 | 3429 | 0.050 |
Why?
|
| Green Chemistry Technology | 1 | 2022 | 10 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 3530 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2011 | 1410 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 2206 | 0.050 |
Why?
|
| Acrylic Resins | 1 | 2021 | 135 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 6345 | 0.040 |
Why?
|
| Glycerides | 1 | 2020 | 67 | 0.040 |
Why?
|
| Pancreatic Elastase | 1 | 2020 | 127 | 0.040 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2019 | 41 | 0.040 |
Why?
|
| Urethane | 1 | 2019 | 36 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2020 | 273 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2021 | 233 | 0.040 |
Why?
|
| Scutellaria | 1 | 2018 | 1 | 0.040 |
Why?
|
| Superoxides | 1 | 2020 | 387 | 0.040 |
Why?
|
| Flavanones | 1 | 2018 | 74 | 0.040 |
Why?
|
| Emulsions | 1 | 2018 | 152 | 0.040 |
Why?
|
| Peroxidase | 1 | 2020 | 609 | 0.030 |
Why?
|
| Carcinogens | 1 | 2019 | 452 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 2018 | 405 | 0.030 |
Why?
|
| Obesity | 1 | 2018 | 12947 | 0.030 |
Why?
|
| Magnetics | 1 | 2018 | 599 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 432 | 0.030 |
Why?
|
| Temperature | 1 | 2021 | 2226 | 0.030 |
Why?
|
| Liposomes | 1 | 2018 | 783 | 0.030 |
Why?
|
| Time Factors | 1 | 2013 | 39969 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 22174 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18255 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 20100 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2018 | 818 | 0.020 |
Why?
|
| Bariatric Surgery | 1 | 2018 | 992 | 0.020 |
Why?
|
| Cell Movement | 1 | 2018 | 5205 | 0.020 |
Why?
|
| Calcium | 1 | 2018 | 5722 | 0.010 |
Why?
|
| Cytokines | 1 | 2020 | 7396 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14665 | 0.010 |
Why?
|
Concepts
(241)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_